Want to see JP:2370 full AI Analyst Report?
MEDINET Co., Ltd. (2370) Stock Price & Analysis
2370 Stock Chart & Stats
- Day’s Range
- JPY 18.00 - JPY 20.00
- 52-Week Range
- JPY 18.00 - JPY 39.00
- Previous Close
- JPY 20.00
- Volume
- N/A
- Average Volume (3M)
- 426.74K
- Market Cap
- JPY 5.69B
- Enterprise Value
- JPY 3.72B
- Total Cash (Recent Filing)
- JPY 5.03B
- Total Debt (Recent Filing)
- JPY 91.32M
- Price to Earnings (P/E)
- ―
- Beta
- 0.62
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Recent revenue growth indicates that MEDINET is expanding its commercial activity despite weak profitability. Continued top-line progress can provide a foundation for operating improvement if the company converts that demand into stronger margins and reduces the gap between sales growth and losses.
Low Leverage
An effectively debt-free balance sheet reduces solvency pressure and limits the burden of interest or refinancing obligations. This gives MEDINET greater financial flexibility than a highly leveraged company while it works to improve profitability and stabilize its capital base.
Healthcare Data Services
MEDINET operates in healthcare IT and clinical data services, supporting clinical operations and data-driven decision-making. Its role in managing and analyzing healthcare information gives the business a defined operating purpose within medical and life-science workflows.
Bears Say
Persistent Losses
Very large and persistent losses indicate that revenue is not yet translating into an economically sustainable business. Because losses have not meaningfully narrowed over time, MEDINET may need a substantial improvement in operating performance before earnings can support durable growth.
Severe Cash Burn
Consistently negative operating and free cash flow means reported losses are creating direct cash outflows rather than remaining mainly non-cash. The sharp FY2025 deterioration increases the need for a credible path to cash-flow improvement and raises pressure on future funding capacity.
Capital Erosion
Declining shareholder equity shows that accumulated losses are eroding the company’s capital base. Even with negligible debt, continued deterioration would reduce financial resilience and could constrain MEDINET’s ability to fund operations or invest in its healthcare data business internally.
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
What is MEDINET Co., Ltd.’s market cap?
When is MEDINET Co., Ltd.’s upcoming earnings report date?
How were MEDINET Co., Ltd.’s earnings last quarter?
Is MEDINET Co., Ltd. overvalued?
Does MEDINET Co., Ltd. pay dividends?
What is MEDINET Co., Ltd.’s EPS estimate?
How many shares outstanding does MEDINET Co., Ltd. have?
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MEDINET Co., Ltd.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kanenao Kubushiro
- Employees
- 107
- Website
- www.medinet-inc.co.jp
- Address
- TRC Center Building, Tokyo, TY, 143-0006, JP
MEDINET Co., Ltd. (2370) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |
